These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Cisplatin, doxorubicin and vindesine in the treatment of advanced non-small cell lung cancer].
    Author: Akiyama J, Sato A, Honda K, Chida K, Watanabe T, Okano H, Okano A, Taniguchi M, Genma H, Aoki H.
    Journal: Gan To Kagaku Ryoho; 1991 Mar; 18(3):419-24. PubMed ID: 1848420.
    Abstract:
    Thirty-seven patients with advanced non-small cell lung cancer were enrolled to evaluate a combination chemotherapy of cisplatin (80 mg/m2), doxorubicin (30 mg/m2) and vindesine (2 mg/m2 x 3). The overall response rate was 27% with ten partial remission. The median survival of whole patients was 11.4 months. The calculation of median survival of the patients with partial remission has not been completed: nine of ten patients have been still alive during the follow-up period of 4 to 16 months. The survival of the patients with PR was significantly different from those of the patients with NC or PD. The major toxicity was myelosuppression. These results indicate that a combination chemotherapy with cisplatin, doxorubicin and vindesine is a moderately effective regimen against non-small cell lung cancer compared to others.
    [Abstract] [Full Text] [Related] [New Search]